Lexington, Massachusetts, United States and Sydney, Australia – July 23, 2012 – GI Dynamics, Inc. (ASX: GID) will hold a conference call to discuss the Company’s financial results for the second quarter and six months ended June 30, 2012, and its business outlook. Stuart Randle, president and chief executive officer, will host the call with Robert Crane, chief financial officer, and Mark Twyman, chief commercial officer.
The Company will file its Appendix 4C following the close in trading on the ASX on Tuesday, July 31, 2012. The briefing call to discuss financial results and business updates will be held at 6 p.m. U.S. EDT on Monday, August 6, 2012 (8 a.m. AEST on Tuesday, August 7, 2012).
Accessing the Briefing Call via Webcast:
A live webcast of the call will be available on the Company’s website at investor.gidynamics.com. The webcast can be directly accessed at: http://www.media-server.com/m/acs/6ac46f3a637553099c2cacc84e186fe1.
Accessing the Briefing Call via Telephone:
For those preferring to listen by telephone, dial-in information follows. Please dial in five minutes prior to the start of the call and provide the passcode 50861352. Regional dial-in numbers:
• United States callers please dial toll-free 1-888-679-8018
• Australia callers please dial toll-free 1-800-729-868
• International callers please dial +1-617-213-4845
Pre-registration is available prior to the call. To pre-register, please go to https://www.theconferencingservice.com/prereg/key.process?key=P78QLBY7A.
Replay archive:
The webcast will be archived for 30 days following the call on the Company’s website at investor.gidynamics.com.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 diabetes and obesity. The company’s flagship product, EndoBarrier®, is a novel, non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic patients and/or obese patients during the implant period. GI Dynamics currently markets EndoBarrier in select regions in Europe, South America and Australia and is planning near-term commercial expansion into additional European countries. EndoBarrier is not approved for sale in the United States and is considered investigational. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com
